Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tennis elbow treatment study ends early: what we learned

NCT ID NCT06846593

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special arm sleeve with embedded semiconductors, combined with injections of platelet-rich plasma and stem cells, could reduce pain and improve elbow function in people with tennis elbow. Only 5 adults aged 18-65 took part before the study was stopped early. The main goal was to measure changes in pain and daily function using standard questionnaires.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Nov 2024

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with ECRB tendinopathy as determined by radiographic assessment or ultrasound imaging. 2. Patients age 18-65 3. Patients who are willing and able to adhere to follow-up schedule and protocol guidelines. 4. Patients who are willing and able to sign corresponding research subject consent form. Exclusion Criteria: 1. Patient has a history of neurological conditions, including multiple sclerosis or Parkinson's disease 2. Patient has severe medical condition, including recent myocardial infarction, unstable angina, heart failure, severe anemia 3. Patient has had prior surgical treatment of the elbow in the last 5 years or injection treatment(s) in the last 2 years 4. Patient has complete tear of ECRB tendon or other surgical indication 5. Patient has chronic pain conditions unrelated to elbow condition 6. Patient has auto-immune or auto-inflammatory diseases 7. Patient has used tobacco within the last 90 days 8. Patient is not within the ages of 18-65 9. Patient has a history of metabolic disorders 10. Patient has an active infection (local or systemic) 11. Patient is unwilling or unable to sign the corresponding research subject consent form 12. Patient meets any other criteria or has any other condition that, in the opinion of the investigator, would prevent them from completing the study or that, in the opinion of the investigator, would confound study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ecrb tendinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bluetail Medical Group

    Chesterfield, Missouri, 63005, United States